Table 2.
Treatment effect by category
| C1 | C2 | C3 | C4 | C5 | C6 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inv. | Con. | Inv. | Con. | Inv. | Con. | Inv. | Con. | Inv. | Con. | Inv. | Con. | ||
|
Cat. #1 |
n (%) | 76 (19.9%) | 62 (16.2%) | 75 (19.6%) | 74 (19.4%) | 53 (13.9%) | 42 (11.0%) | ||||||
| n per arm | 47 | 29 | 31 | 31 | 42 | 33 | 53 | 21 | 35 | 18 | 27 | 15 | |
| Mean mRS | 3.57 | 4.03 | 4.06 | 3.71 | 2.57 | 2.82 | 2.89 | 3.33 | 2.43 | 2.72 | 3.04 | 3.13 | |
| Delta mRS (SD) | −0.46 (1.92) | 0.35 (2.08) | −0.25 (2.00) | −0.44 (1.81) | −0.29 (1.87) | −0.09 (1.80) | |||||||
|
Cat. #2 |
n (%) | 52 (13.6%) | 76 (19.9%) | 65 (17.0%) | 76 (19.9%) | 49 (12.8%) | 64 (16.8%) | ||||||
| n | 30 | 22 | 38 | 38 | 48 | 17 | 47 | 29 | 33 | 16 | 39 | 25 | |
| Mean mRS | 3.13 | 3.41 | 2.37 | 3.37 | 3.23 | 2.88 | 3.21 | 2.93 | 3 | 3.88 | 3.41 | 3.68 | |
| Delta mRS (SD) | −0.28 (2.07) | −1.00 (1.96) | 0.35 (1.92) | 0.28 (2.12) | −0.88 (1.67) | −0.27 (1.96) | |||||||
Cat #1 indicates categorization scheme #1 in which patients are categorized based on time and location of the arterial occlusion. Cat #2 indicates categorization scheme #2 in which patients are categorized only based on time. Cx indicates a patient category. See figure 1 for the exact criteria that define each patient category in categorization scheme #1 and #2. Inv. indicates the investigational treatment arm in the IMS III trial (intravenous tPA plus endovascular therapy); Con. indicates the control arm (intravenous tPA alone); n indicates number of subjects; mRS indicates modified Rankin Scale; and SD indicates standard deviation.